SBI Equity Minimum Variance Fund
The scheme seeks to provide long term capital appreciation by investing in a diversified basket of companies in Nifty 50 Index while aiming for minimizing the portfolio volatility.
Growthvine rating: 2/5 — ranked #95 of 184 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹22.24 (as of 2026-10-01) |
|---|
| AUM | ₹208 Cr |
|---|
| Expense ratio | 0.65% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Sukanya Ghosh |
|---|
| Exit load | 0.5% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 6.82% |
|---|
| Sharpe ratio | 0.25 |
|---|
| Standard deviation | 14.51% |
|---|
| Max drawdown | −32.98% |
|---|
| Alpha | -2.46 |
|---|
| Beta | 0.89 |
|---|
Over 5 years, captured 82.8% of Nifty 500's upside and 81.6% of its downside.
Market cap allocation
| Large cap | 95.9% |
|---|
| Mid cap | 4.1% |
|---|
| Small cap | 0.0% |
|---|
Concentration
| Top 5 holdings | 35.6% |
|---|
| Top 10 holdings | 57.3% |
|---|
| Total holdings | 50 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 8.5%
- Nestle India Ltd. — 8.3%
- Apollo Hospitals Enterprises Ltd. — 8.2%
- Hindustan Unilever Ltd. — 5.7%
- TATA CONSUMER PRODUCTS LIMITED — 4.9%
- ITC Ltd — 4.9%
- Cipla Ltd. — 4.7%
- Tech Mahindra Limited — 4.6%
- Coal India Limited — 4.3%
- Dr. Reddys Laboratories Ltd. — 3.1%
Top sectors
- Pharma & Biotech — 16.3%
- FMCG — 10.6%
- Software & Services — 9.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −10.1% | Q4 (Bottom) | #143 of 167 |
| 2025 | 7.1% | Q2 | #39 of 132 |
| 2024 | 8.1% | Q4 (Bottom) | #85 of 86 |
| 2023 | 28.0% | Q3 | #37 of 66 |
| 2022 | 6.2% | Q2 | #23 of 55 |